Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran

References

• DiMicheleDMNeufeldEJHemophilia. A new approach to an old diseaseHematol Oncol Clin North Am199812131513449922937
   PubMed Web of Science ®Google Scholar
• DiMicheleDInhibitors to factor VIII: epidemiology and treatmentLeeCAHootsKBerntorpETextbook of HemophiliaOxfordBlackwell Science20056470
   Google Scholar
• UK Hemophilia Centre Doctors’ OrganizationThe incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–1999J Thromb Haemost200421047105415219185
   PubMed Web of Science ®Google Scholar
• MannucciPMGringeriAPeyvandiFSantagostinoEFactor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers)Hemophilia2007136568
   PubMed Web of Science ®Google Scholar
• GringeriAMannucciPMfor the Italian Association of Hemophilia CentresItalian guidelines for the diagnosis and treatment of patients with hemophilia and inhibitorsHemophilia200511611619
   PubMed Web of Science ®Google Scholar
• RodriguezNIHootsWKAdvances in hemophilia: experimental aspects and therapyPediatric Clin N Am200855357376
   Web of Science ®Google Scholar
• GringeriAMantovaniLGScaloneLMannucciPMCost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study GroupBlood20031022358236312816859
   PubMed Web of Science ®Google Scholar
• WhiteGCRosendaalFAledortLMDefinitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and HomeostasisThromb Haemost20018556011307831
   PubMed Web of Science ®Google Scholar
• HayCRBaglinTPCollinsPWThe diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Hemophilia Centre Doctors’ Organization (UKHCDO)Br J Haematol2000111789011091185
   PubMed Web of Science ®Google Scholar
• DiMicheleDMHootsWKPipeSWInternational workshop on immune tolerance induction: consensus recommendationsHemophilia200713Suppl 1122
   PubMed Web of Science ®Google Scholar
• DiMicheleDRivardGHayCAntunesSInhibitors in hemophilia: clinical aspectsHemophilia200410Suppl 4140145
   PubMed Web of Science ®Google Scholar
• LeissingerCAUse of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in hemophilia patients with inhibitorsHemophilia19995Suppl 32532
   Google Scholar
• AstermarkJDonfieldSMDiMicheleDA randomized comparison of bypassing agents in hemophilia complicated by an inhibitorBlood200710954655116990605
   PubMed Web of Science ®Google Scholar
• HoAYHeightSESmithMPImmune tolerance therapy for hemophiliaDrugs20006054755411030466
   PubMed Web of Science ®Google Scholar
• WightJPaisleySKnightCImmune tolerance induction in patients with hemophilia A with inhibitors: a systematic reviewHemophilia20039436463
   PubMed Web of Science ®Google Scholar
• BerntorpEOptions for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolyticsHemophilia200612Suppl 66265 discussion 5–6
   Web of Science ®Google Scholar
• DiMicheleDMHayCRThe international immune tolerance study: a multicenter prospective randomized trial in progressJ Thromb Haemost200642271227316848866
   PubMed Web of Science ®Google Scholar
• OldenburgJSchwaabRBrackmannHHInduction of immune tolerance in hemophilia A inhibitor patients by the Bonn protocol: predictive parameter for therapy duration and outcomeVox Sang199977Suppl 1495410529689
   PubMed Web of Science ®Google Scholar
• Mauser-BunschotenEPRoosendaalGvan den BergHMLow-dose immune tolerance therapy: the van creveld modelVox Sang199670Suppl 166678869472
   PubMed Web of Science ®Google Scholar
• FreiburghausCBerntorpEEkmanMTolerance induction using the Malmö treatment model 1982–1995Hemophilia199953239
   PubMed Web of Science ®Google Scholar
• NilssonIMBerntorpEZettervallOInduction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIIIN Engl J Med19883189479503127711
   PubMed Web of Science ®Google Scholar
• HilgartnerMAledortLAndesAGillJEfficacy and safety of vapor- heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study GroupTransfusion1990306266302402777
   PubMed Web of Science ®Google Scholar
• NegrierCGoudemandJSultanYMulticenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing ActivityThromb Haemost199777111311199241742
   PubMed Web of Science ®Google Scholar
• SrivastavaAFactor replacement therapy in hemophilia: are there models for developing countries?Hemophilia20039391396
   PubMed Web of Science ®Google Scholar
• ShapiroADGilchristGSHootsWKProspective, randomised trial of two doses of rFVIIa (NovoSeven) in hemophilia patients with inhibitors undergoing surgeryThromb Haemost1998807737789843170
   PubMed Web of Science ®Google Scholar
• ArkinSBleiFFettenJHuman coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency use programme in patients with severe hemophilia or with acquired inhibitorsBlood Coagul Fibrinolysis20001125525910870806
   PubMed Web of Science ®Google Scholar
• TjonnfjordGEActivated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experienceHemophilia200410Suppl 24145
   Web of Science ®Google Scholar
• AbshireTKenetGRecombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitorsJ Thromb Haemost2004289990915140125
   PubMed Web of Science ®Google Scholar
• ParameswaranRShapiroADGillJCDose effect and efficacy of recombinant factor VIIa (rFVIIa) in the treatment of hemophilia patients with inhibitors: analysis from the hemophilia research society (HRS) registryBlood200210097a
   Web of Science ®Google Scholar
• Authors’ dataExtracted from National Disease Registry, Iranian Ministry of Health [Arabic.] Available from: http://fdo.behdasht.gov.ir/Accessed November 1, 2011
   Google Scholar
• KesslerCMAledortLMThe economics of immune tolerance and treatment of hemophiliacs with inhibitorsVox Sang199670Suppl 174768869476
   PubMed Web of Science ®Google Scholar
• AledortLMInhibitors to coagulation: can we afford immune tolerance induction regimens?Vox Sang199670Suppl 177788869477
   PubMed Web of Science ®Google Scholar
• KnightCPaisleySWightJJonesMLEconomic modelling of different treatment strategies for hemophilia A with high-responding inhibitorsHemophilia20039521540
   PubMed Web of Science ®Google Scholar
• LippertBBergerKBerntorpECost effectiveness of hemophilia treatment: across-national assessmentBlood Coagul Fibrinolysis20051647748516175006
   PubMed Web of Science ®Google Scholar
• ColowickABBohnRLAvornJEwensteinBMImmune tolerance induction in hemophilia patients with inhibitors: costly can be cheaperBlood2000961698170210961866
   PubMed Web of Science ®Google Scholar
• TeitelJMRecombinant Factor VIIa versus aPCCs in hemophiliacs with inhibitor: treatment and cost considerationsHemophilia19995Suppl 34349
   Google Scholar
• BohnRLAledortLMPutnamKGThe economic impact of factor VIII inhibitors in patients with hemophiliaHemophilia2004106368
   PubMed Web of Science ®Google Scholar
• ChangHSherGDBlanchetteVSTeitelJMThe impact of inhibitors on the cost of clotting factor replacement therapy in hemophilia A in CanadaHemophilia19995247252
   PubMed Web of Science ®Google Scholar
• SchrammWExperience with prophylaxis in GermanySemin Hematol19933012158367737
   PubMed Web of Science ®Google Scholar